Our Intermediate-Term Corporate Strategy

President and Chief Executive Officer Yan HaoThe CRO, SMO, and pre-clinical businesses comprise the core of the EPS Group. We also provide staffing service, pharmaceutical- and medical- information system development, as well as software development and CRO services in China, South East Asia, and Oceania. There are powerful synergies between these various businesses, and we actively seek to turn them into new business opportunities. Here are more detailed descriptions of the strategies for each of our business fields.

Fortifying Our CRO Function to Become a Full-service Provider

In order to better respond to various outsourcing needs arising from the drug development process, we will continue to fortify our position as a comprehensive provider offering a wide range of services, from clinical trial planning to new drug application and approval. We have added a new consolidated subsidiary to our Group: LSG Corporation, which specializes in conducting pre-clinical studies. And, as part of our efforts to fortify our capabilities as a CRO providing full support for drug development, we are increasing the number of medical institutions conducting phase I studies on healthy volunteers.

Promotion of the SMO Business

The implementation of the GCP guidelines in 1998 (Footnote 1) has greatly increased the burden of clinical study on small-to-medium-sized medical institutions, and has drawn increasing attention to SMOs providing ethical and rational support to medical institutions. Against this backdrop, we expect further expansion in applications for clinical study support services. Therefore, we will aggressively expand our efforts in the SMO business through the fortification of our subsidiary, EP-Mint Co., Ltd., and leverage the synergies within our CRO business.

Use of Advanced Information Technologies

In our data management (Footnote 2) and monitoring (Footnote 3) businesses, we will increase the use of information technologies as well as taking full advantage of the Internet in our clinical study. Moreover, using our in-house expertise, we aim to develop new business by creating project teams to provide IT services to pharmaceutical companies and medical institutions. EPS constantly seeks to increase its corporate value. In the pursuit of this goal, we ask for your continued understanding and support.

July 2005
EPS Corporation
Chairman & President CEO, Yan Hao

  1. GCP is an acronym for "Good Clinical Practice," which is the standard defined by the Ministry of Health and Welfare for the clinical studies. GCP is the standard for all medical institutions, doctors and companies performing clinical studies.
  2. The data management business is the assessment, stabilization, calculation, and analysis of various data gathered from clinical studies, and the creation of presentation materials based on the findings of this data.
  3. The monitoring business means the process of visiting medical institutions and interviewing doctors participating in clinical study, explaining the protocols (explaining the purpose of the studies, design, methodology, then performing statistical reviews and creating documents about the organizations and facilities responsible for the studies), checking the progress of the studies, and filling out, gathering and surveying the results.

[ Contact ] Public Relations Office TEL +81-3-5684-7826 / FAX +81-3-5804-0361

[ Last Update ]

Page Top